Morphological prerequisites for the formation of fascial duplication in the elimination of damage to the anterior rectal wall during prostatectomy von Yurgel, Yu. N., Alekseev, B. Ya, Kopyltsov, E. I., Leonov, O. V., Sikhvardt, I. A., Leonova, A. O., Stepanov, S. S., Koroleva, S. A.

Volltext

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma von Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

Volltext

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma von Powles, Thomas, Park, Se Hoon, Voog, Eric, Caserta, Claudia, Valderrama, Begoña P, Gurney, Howard, Kalofonos, Haralabos, Radulović, Siniša, Demey, Wim, Ullén, Anders, Loriot, Yohann, Sridhar, Srikala S, Tsuchiya, Norihiko, Kopyltsov, Evgeny, Sternberg, Cora N, Bellmunt, Joaquim, Aragon-Ching, Jeanny B, Petrylak, Daniel P, Laliberte, Robert, Wang, Jing, Huang, Bo, Davis, Craig, Fowst, Camilla, Costa, Nuno, Blake-Haskins, John A, di Pietro, Alessandra, Grivas, Petros

Volltext

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma von Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K

Volltext

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer von Smith, Matthew R, Hussain, Maha, Saad, Fred, Fizazi, Karim, Sternberg, Cora N, Crawford, E. David, Kopyltsov, Evgeny, Park, Chandler H, Alekseev, Boris, Montesa-Pino, Álvaro, Ye, Dingwei, Parnis, Francis, Cruz, Felipe, Tammela, Teuvo L.J, Suzuki, Hiroyoshi, Utriainen, Tapio, Fu, Cheng, Uemura, Motohide, Méndez-Vidal, María J, Maughan, Benjamin L, Joensuu, Heikki, Thiele, Silke, Li, Rui, Kuss, Iris, Tombal, Bertrand

Volltext

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma von Choueiri, Toni K, Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas, Chang, Yen-Hwa, Hajek, Jaroslav, Symeonides, Stefan N, Lee, Jae Lyun, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Mahave, Mauricio, Haas, Naomi B, Sawrycki, Piotr, Gurney, Howard, Chevreau, Christine, Melichar, Bohuslav, Kopyltsov, Evgeniy, Alva, Ajjai, Burke, John M, Doshi, Gurjyot, Topart, Delphine, Oudard, Stephane, Hammers, Hans, Kitamura, Hiroshi, Bedke, Jens, Perini, Rodolfo F, Zhang, Pingye, Imai, Kentaro, Willemann-Rogerio, Jaqueline, Quinn, David I, Powles, Thomas

Volltext

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, pl... von Petrylak, Daniel P, Prof, Vogelzang, Nicholas J, MD, Budnik, Nikolay, MD, Wiechno, Pawel Jan, MD, Sternberg, Cora N, Prof, Doner, Kevin, MD, Bellmunt, Joaquim, MD, Burke, John M, MD, de Olza, Maria Ochoa, MD, Choudhury, Ananya, PhD, Gschwend, Juergen E, Prof, Kopyltsov, Evgeny, MD, Flechon, Aude, MD, Van As, Nicolas, MD, Houede, Nadine, MD, Barton, Debora, MD, Fandi, Abderrahim, MD, Jungnelius, Ulf, MD, Li, Shaoyi, PhD, de Wit, Ronald, Prof, Fizazi, Karim, Prof

Volltext

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma von Choueiri, Toni K., Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Tom, Symeonides, Stefan N., Hajek, Jaroslav, Chang, Yen-Hwa, Lee, Jae-Lyun, Sarwar, Naveed, Haas, Naomi B., Gurney, Howard, Sawrycki, Piotr, Mahave, Mauricio, Gross-Goupil, Marine, Zhang, Tian, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Kopyltsov, Evgeniy, Alva, Ajjai, Oudard, Stephane, Topart, Delphine, Hammers, Hans, Kitamura, Hiroshi, McDermott, David F., Silva, Adriano, Winquist, Eric, Cornell, Jerry, Elfiky, Aymen, Burgents, Joseph E., Perini, Rodolfo F., Powles, Thomas

Volltext

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial von Hussain, Maha, Tombal, Bertrand, Saad, Fred, Fizazi, Karim, Sternberg, Cora N, Crawford, E David, Shore, Neal, Kopyltsov, Evgeny, Kalebasty, Arash Rezazadeh, Bögemann, Martin, Ye, Dingwei, Cruz, Felipe, Suzuki, Hiroyoshi, Kapur, Shivani, Srinivasan, Shankar, Verholen, Frank, Kuss, Iris, Joensuu, Heikki, Smith, Matthew R

Volltext

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma von Loriot, Yohann, Necchi, Andrea, Park, Se Hoon, Garcia-Donas, Jesus, Huddart, Robert, Burgess, Earle, Fleming, Mark, Rezazadeh, Arash, Mellado, Begoña, Varlamov, Sergey, Joshi, Monika, Duran, Ignacio, Tagawa, Scott T, Zakharia, Yousef, Zhong, Bob, Stuyckens, Kim, Santiago-Walker, Ademi, De Porre, Peter, O’Hagan, Anne, Avadhani, Anjali, Siefker-Radtke, Arlene O

Volltext

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial von Smith, Matthew R, Scher, Howard I, Sandhu, Shahneen, Efstathiou, Eleni, Lara, Primo N, Yu, Evan Y, Chi, Kim N, Ståhl, Olof, Olmos, David, Danila, Daniel C, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, Lopez-Gitlitz, Angela, Parnis, Francis, Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Ferguson, Thomas, Luyten, Daisy, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Mermershtain, Wilmosh, Peer, Avivit, Sella, Avishay, Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Choi, Young-Deuk, Gafanov, Rustem A., Kopyltsov, Evgeniy, Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Attard, Gerhardt, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Emamekhoo, Hamid, Pinski, Jacek K.

Volltext

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms von Grünwald, Viktor, Powles, Thomas, Eto, Masatoshi, Kopyltsov, Evgeny, Rha, Sun Young, Porta, Camillo, Motzer, Robert, Hutson, Thomas E, Méndez-Vidal, María José, Hong, Sung-Hoo, Winquist, Eric, Goh, Jeffrey C, Maroto, Pablo, Buchler, Tomas, Takagi, Toshio, Burgents, Joseph E, Perini, Rodolfo, He, Cixin, Okpara, Chinyere E, McKenzie, Jodi, Choueiri, Toni K

Volltext

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study von Siefker-Radtke, Arlene O, Necchi, Andrea, Park, Se Hoon, García-Donas, Jesús, Huddart, Robert A, Burgess, Earle F, Fleming, Mark T, Rezazadeh Kalebasty, Arash, Mellado, Begoña, Varlamov, Sergei, Joshi, Monika, Duran, Ignacio, Tagawa, Scott T, Zakharia, Yousef, Akapame, Sydney, Santiago-Walker, Ademi E, Monga, Manish, O'Hagan, Anne, Loriot, Yohann, Necchi, Andrea, Loriot, Yohann, Park, Se Hoon, Tagawa, Scott, Flechon, Aude, Alexeev, Boris, Varlamov, Sergey, Huddart, Robert, Vano, Yann, Gasparro, Donatello, Hamzaj, Alketa, Kopyltsov, Eugeniy, Gracia Donas, Jesus, Mellado, Begona, Parikh, Omi, Schatteman, Peter, Culine, Stephane, Houédé, Nadine, Zanetta, Sylvie, Facchini, Gaetano, Scagliotti, Giorgio, Schinzari, Giovanni, Lee, Jae Lyun, Shkolnik, Mikhail, Fleming, Mark, Joshi, Monica, O'Donnell, Peter, Stöger, Herbert, Decaestecker, Karel, Dirix, Luc, Machiels, Jean Pascal, Borchiellini, Dephine, Delva, Remy, Rolland, Frederic, Hadaschik, Boris, Retz, Margitta, Rosenbaum, Eli, Basso, Umberto, Mosca, Alessandra, Shin, Dong Bok, Cebotaru, Cristina, Duran, Ignacio, Moreno, Victor, Perez Gracia, Jose Luis, Pinto, Alvaro, Su, Wen-Pin, Wang, Shian-Shiang, Schnadig, Ian, Srinivas, Sandhya, Vogelzang, Nicholas, Loidl, Wolfgang, Meran, Johannes, Gross Goupil, Marine, Joly, Florence, Imkamp, Florian, Krege, Susanne, May, Matthias, Schultze-Seemann, Wolfgang, Strauss, Arne, Zimmermann, Uwe, Keizman, Daniel, Peer, Avivit, Sella, Avishai, Berardi, Rossana, De Giorgi, Ugo, Sternberg, Cora Nanette, Rha, Sun Young, Bulat, Iurie, Izmailov, Adel, Matveev, Vsevolod, Vladimirov, Vladimir, Carles, Joan, Font, Albert, Saez, Maribel, Syndikus, Isabel, Tarver, Kathryn, Appleman, Leonard, Burke, John, Dawson, Nancy, Jain, Sharad, Zakharia, Yousef

Volltext

A0647 - Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial von Tombal, B., Hussain, M., Saad, F., Fizazi, K., Shore, N., Kopyltsov, E., Bögemann, M., Mendez-Vidal, M.J., Littleton, N., Srinivasan, S., Verholen, F., Smith, M.R.

Volltext

Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial von Tombal, B., Hussain, M., Saad, F., Fizazi, K., Shore, N., Kopyltsov, E., Bögemann, M., Mendez-Vidal, M.J., Littleton, N., Srinivasan, S., Verholen, F., Smith, M.R.

Volltext

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms von Grünwald, Viktor, Powles, Thomas, Eto, Masatoshi, Kopyltsov, Evgeny, Rha, Sun Young, Porta, Camillo, Motzer, Robert, Hutson, Thomas E, Méndez-Vidal, María José, Hong, Sung-Hoo, Winquist, Eric, Goh, Jeffrey C, Maroto, Pablo, Buchler, Tomas, Takagi, Toshio, Burgents, Joseph E, Perini, Rodolfo, He, Cixin, Okpara, Chinyere E, McKenzie, Jodi, Choueiri, Toni K

Volltext

LBA68 Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE t... von Saad, F., Vjaters, E., Shore, N.D., Olmos, D., Xing, N., Gomes, A.J.P.D.S., Mota, A.C.A., Salman, P., Jievaltas, M., Ulys, A., Jakubovskis, M., Kopyltsov, E., Han, W., Nevalaita, L., Testa, I., Le Berre, M-A., Kuss, I., Kunhiparambath, H.

Volltext

Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer von Powles, Thomas, Park, Se Hoon, Voog, Eric, Caserta, Claudia, Valderrama, Begoña P, Gurney, Howard, Kalofonos, Haralabos, Radulovic, Sinisa, Demey, Wim, Ullén, Anders, Loriot, Yohann, Sridhar, Srikala S, Tsuchiya, Norihiko, Kopyltsov, Evgeny, Sternberg, Cora N, Bellmunt, Joaquim, Aragon-Ching, Jeanny B, Petrylak, Daniel P, Laliberte, Robert J, Huang, Bo, Costa, Nuno, Blake-Haskins, John A, Grivas, Petros

Volltext

Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study von Feyerabend, S., Shore, N., Smith, M., Kopyltsov, E., Antonyan, I., Damber, J., Gasparro, D., Yildirim, A., Hellstrom, M., Vjaters, E., Ortiz, J., Srinivasan, S., Sarapohja, T., Fizazi, K.

Volltext

Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate c... von Tombal, B., Saad, F., Fizazi, K., Sternberg, C.N., Crawford, E.D., Gratzke, C., Grabbert, M., Vilaseca, A., Shore, N., Kopyltsov, E., Bögemann, M., Kapur, S., Srinivasan, S., Verholen, F., Kuss, I., Joensuu, H., Smith, M.R., Hussain, M.

Volltext